OQ-08: Are treatments as effective and safe in perimenopause as after menopause?
Status: open. Status as of . Version 1.0.
This page describes research, not your treatment. Talk to your own doctor about your situation.
What we can say today
Researchers do not yet know whether results from studies of women after menopause hold for women in perimenopause. Perimenopause, the years of change before periods end, is rarely reported as a separate group in the evidence we checked.
Why it matters
Perimenopause is when many people first notice symptoms. Cycles still come and go, and the body is in a different place than it is years after the final period. A result found in women long past menopause may not carry over to women still in the transition.
For research, perimenopause is hard to study. It has no single test (see OQ-09), it varies from person to person, and it can last years. Enrolling women who are clearly past menopause keeps a trial group simple, but leaves the earlier stage less covered.
What is known
- A 2026 Cochrane systematic review on long term hormone therapy for perimenopausal and postmenopausal women included 24 studies with 45 660 participants. About 30% of participants were aged 50 to 59. Its abstract does not report results for women in perimenopause as a separate group.
- A draft report from an independent NIH Pathways to Prevention panel (draft dated September 2026, open for public comment until 30 October 2026; draft, subject to change) states: "This evidence is largely focused on older White women, on menopause and postmenopause (rather than perimenopause), and on hormonal treatments rather than ..." The panel based this on its systematic evidence review (SER). It adds: "The SER found very limited evidence concerning how treatment outcomes vary by timing or type of menopause, particularly because few studies focused on perimenopausal women." [2] (See also OQ-10.)
- A 2026 review in Psychoneuroendocrinology states that research and funding inequities have left significant gaps in knowledge about the menopausal transition, and that accurate staging is critically needed to understand how perimenopause raises the risk of adverse outcomes. [3]
- A 2005 NIH State of the Science conference summary in the American Journal of Medicine identified important gaps in understanding the natural history of the menopausal transition. Read together with the 2026 sources, it shows the gap is long standing. [4]
Why it is still open
A systematic review can only pool what trials have done. If few trials enrol women in perimenopause, or do not report them separately, the review cannot say much about them. Results from older women may differ for reasons that are hard to separate: age itself, time since menopause, other health conditions and the hormone background the treatment acts on. The NIH panel draft points to exactly this problem: few studies focus on perimenopausal women, so little can be said about how outcomes differ by timing.
What would answer it
Randomized trials that enrol women in perimenopause, define the stage with a recognised staging system, and report results separately for that group. Outcomes would need to cover both symptom relief and harms, with follow-up long enough to see effects that take years. A systematic review that pulls out perimenopause results from existing trials, where the data allow, would also help.
Sources
1. Bofill Rodriguez, et al. Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev. 2026. https://doi.org/10.1002/14651858.CD004143.pub7 PMID 42695385. Verified on 2026-10-12.
2. NIH Office of Disease Prevention. Improving Health During the Menopausal Transition: Findings from the Pathways to Prevention Program. Independent Panel DRAFT report, September 2026, lines 70 to 71 and 190 to 191. https://prevention.nih.gov/sites/g/files/mnhszr241/files/2026-10/Menopause-P2P-Independent-Panel-Report-Draft.pdf Verified on 2026-10-13. Draft: to be rechecked once final.
3. Huibregtse, et al. Considerations and practical recommendations for identifying perimenopause in longitudinal research. Psychoneuroendocrinology. 2026. https://doi.org/10.1016/j.psyneuen.2026.107748 PMID 41576711. Verified on 2026-10-13.
4. Sherman, et al. Research opportunities for reducing the burden of menopause-related symptoms. Am J Med. 2005. https://doi.org/10.1016/j.amjmed.2005.12.004 PMID 16414344. Verified on 2026-10-13.
Related on MenoDerm
- /qa/what-should-i-ask-about-hormones
- /methodology#open-questions
- Open questions OQ-09 and OQ-10
Status history
| Date | From | To | Reason | Source |
|---|---|---|---|---|
| (none) | open | Page created, status set | (none) |
Cite this page
MenoDerm Open Question OQ-08, version 1.0, , /open-questions/are-perimenopause-treatments-understudied.
MenoDerm explains research. It does not give medical advice and is not a clinic. Talk to your own doctor about your situation. The status describes the research, not your situation.